Free Trial
NYSE:RCUS

Arcus Biosciences (RCUS) Stock Price, News & Analysis

Arcus Biosciences logo
$15.91 -0.05 (-0.31%)
(As of 04:45 PM ET)

About Arcus Biosciences Stock (NYSE:RCUS)

Key Stats

Today's Range
$15.46
$16.00
50-Day Range
$14.30
$18.44
52-Week Range
$13.52
$20.31
Volume
157,238 shs
Average Volume
731,876 shs
Market Capitalization
$1.46 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.00
Consensus Rating
Buy

Company Overview

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Arcus Biosciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
61st Percentile Overall Score

RCUS MarketRank™: 

Arcus Biosciences scored higher than 61% of companies evaluated by MarketBeat, and ranked 447th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arcus Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Arcus Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Arcus Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Arcus Biosciences are expected to decrease in the coming year, from ($3.20) to ($4.82) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arcus Biosciences is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arcus Biosciences is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arcus Biosciences has a P/B Ratio of 2.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    16.69% of the float of Arcus Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Arcus Biosciences has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Arcus Biosciences has recently increased by 6.08%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Arcus Biosciences does not currently pay a dividend.

  • Dividend Growth

    Arcus Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.69% of the float of Arcus Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Arcus Biosciences has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Arcus Biosciences has recently increased by 6.08%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Arcus Biosciences has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Arcus Biosciences this week, compared to 5 articles on an average week.
  • Search Interest

    2 people have searched for RCUS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arcus Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,079.00 in company stock.

  • Percentage Held by Insiders

    12.30% of the stock of Arcus Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    92.89% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arcus Biosciences' insider trading history.
Receive RCUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RCUS Stock News Headlines

Arcus Biosciences Announces New Employment Inducement Grants
70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!
Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.
See More Headlines

RCUS Stock Analysis - Frequently Asked Questions

Arcus Biosciences' stock was trading at $19.10 at the start of the year. Since then, RCUS shares have decreased by 16.7% and is now trading at $15.91.
View the best growth stocks for 2024 here
.

Arcus Biosciences, Inc. (NYSE:RCUS) posted its earnings results on Wednesday, November, 6th. The company reported ($1.00) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.06. Arcus Biosciences's revenue was up 50.0% on a year-over-year basis.

Arcus Biosciences (RCUS) raised $99 million in an initial public offering (IPO) on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.

Top institutional investors of Arcus Biosciences include FMR LLC (4.88%), State Street Corp (3.29%), Point72 Asset Management L.P. (2.66%) and Geode Capital Management LLC (1.34%). Insiders that own company stock include Gilead Sciences, Inc, Juan C Jaen, Terry J Rosen, Jennifer Jarrett, Robert C Goeltz II, Carolyn C Tang and Alexander Azoy.
View institutional ownership trends
.

Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arcus Biosciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
11/06/2024
Today
12/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Fax
N/A
Employees
500
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$34.00
High Stock Price Target
$44.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+113.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$-307,000,000.00
Net Margins
-102.66%
Pretax Margin
-102.28%

Debt

Sales & Book Value

Annual Sales
$263 million
Book Value
$6.17 per share

Miscellaneous

Free Float
80,256,000
Market Cap
$1.46 billion
Optionable
Optionable
Beta
0.88
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (NYSE:RCUS) was last updated on 12/24/2024 by MarketBeat.com Staff
From Our Partners